Document Detail

Heparan sulfate enhances invasion by human colon carcinoma cell lines through expression of CD44 variant exon 3.
MedLine Citation:
PMID:  11751503     Owner:  NLM     Status:  MEDLINE    
CD44 variant exon (CD44v) 3 is a heparan sulfate-binding isoform of CD44. The role of CD44v3 in invasion and metastasis associated with heparan sulfate in colon cancer cell lines and cases of colon cancer was examined. Expression of CD44v3 mRNA and protein was observed in five of six human colorectal cancer cell lines. Colo320 and WiDr cells expressed CD44v3 at high levels. Heparan sulfate treatment increased the invasive activity of Colo320 and WiDr cells to rates 14.3 and 12.6 times higher, respectively, than that of untreated cells. However, heparan sulfate treatment did not affect cell growth. Repression of CD44v3 protein production by antisense S-oligodeoxynucleotide treatment reduced the binding affinities and capacities for heparan sulfate by Colo320 and WiDr cells in comparison with that of control cells, and it also reduced the invasiveness of both cell lines to one-fifth that of control cells. In heparan sulfate-treated Colo320 cells, the levels of CD44v3 protein in the Triton X-100-insoluble fraction and moesin-precipitated fraction were increased, suggesting that heparan sulfate treatment facilitates association of CD44 molecules with the cytoskeleton. Immunohistochemical analysis showed CD44v3 to be expressed in 21 of 37 (57%) colorectal cancer cases. Positive CD44v3 expression was associated with more advanced pathological stage and poorer prognosis than negative CD44v3 expression. These data support a role for CD44v3 in invasion and metastasis by colorectal carcinoma cells.
H Kuniyasu; N Oue; M Tsutsumi; E Tahara; W Yasui
Related Documents :
16879263 - Using a quality control approach to define an 'adequately cellular' liquid-based cervic...
11945013 - Spontaneous squamous cell carcinoma of the tongue and multiple bronchioloalveolar carci...
21080333 - Reconstitution of human mcf-7 breast cancer cells with caspase-3 does not sensitize the...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Clinical cancer research : an official journal of the American Association for Cancer Research     Volume:  7     ISSN:  1078-0432     ISO Abbreviation:  Clin. Cancer Res.     Publication Date:  2001 Dec 
Date Detail:
Created Date:  2001-12-25     Completed Date:  2002-03-27     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  9502500     Medline TA:  Clin Cancer Res     Country:  United States    
Other Details:
Languages:  eng     Pagination:  4067-72     Citation Subset:  IM    
Department of Oncological Pathology, Cancer Center, Nara Medical University, 840 Shijo-cho, Kashihara 634-8521, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antigens, CD / genetics*
Antigens, CD44 / genetics*
Base Sequence
Cell Division / drug effects
Colonic Neoplasms / genetics,  mortality,  pathology*,  surgery
Colorectal Neoplasms / genetics,  pathology
Cytoskeleton / drug effects
Gene Expression Regulation, Neoplastic / drug effects
Genetic Variation*
Heparitin Sulfate / pharmacokinetics,  pharmacology*
Neoplasm Invasiveness
Oligodeoxyribonucleotides, Antisense / genetics
Protein Isoforms / genetics
RNA, Messenger / genetics
Reverse Transcriptase Polymerase Chain Reaction
Survival Rate
Time Factors
Tumor Cells, Cultured
Reg. No./Substance:
0/Antigens, CD; 0/Antigens, CD44; 0/CD44V3,8-10; 0/Oligodeoxyribonucleotides, Antisense; 0/Protein Isoforms; 0/RNA, Messenger; 0/Thionucleotides; 9050-30-0/Heparitin Sulfate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer.
Next Document:  Alphav integrin expression is a novel marker of poor prognosis in advanced-stage ovarian carcinoma.